African Countries with Highest Chinese Loans – 2024 Data
- From 2000 to 2024, 42 Chinese lenders inked 1,319 loans totaling $180.87 billion with 49 African states and seven regional entities.
- Food and Drug Governance (FDA) is proposing to revoke the approval of several biosimilar insulin products due to concerns about their interchangeability with their reference products.
- Interchangeability is a key concept for biosimilars, meaning they can be substituted for the reference product without the intervention of a healthcare professional, similar to how generic drugs...
From 2000 to 2024, 42 Chinese lenders inked 1,319 loans totaling $180.87 billion with 49 African states and seven regional entities.
The U.S. Food and Drug Governance (FDA) is proposing to revoke the approval of several biosimilar insulin products due to concerns about their interchangeability with their reference products.
Interchangeability is a key concept for biosimilars, meaning they can be substituted for the reference product without the intervention of a healthcare professional, similar to how generic drugs are substituted for brand-name drugs. Though, the FDA has raised concerns that some biosimilar insulin products may not meet the requirements for interchangeability.
The FDA’s proposal affects biosimilar insulin products made by multiple manufacturers. The agency has cited concerns about data submitted by the manufacturers, as well as reports of adverse events experienced by patients who switched to the biosimilar products.
The FDA is seeking public comment on its proposal before making a final decision. If the proposal is finalized, it could considerably impact the availability of biosimilar insulin products in the U.S. and possibly increase costs for patients with diabetes.
the FDA’s move comes as the agency faces increasing scrutiny over its biosimilar approval process. Some patient advocacy groups have argued that the agency has been too speedy to approve biosimilars without adequately assessing their safety and efficacy.
The proposed revocation of approval for thes biosimilar insulin products is a significant development that could have far-reaching consequences for patients with diabetes and the pharmaceutical industry.
Meanwhile, fossil fuel projects, electricity-generating, and ICT projects received almost no fresh loans in 2024.
In Kenya, all infrastructure loans in 2024 were denominated in RMB, a shift from the USD-dominated borrowing that characterized the 2010s.
According to a Boston University analysis,net debt transfers from China to developing countries fell in 2022 and 2023,with governments repaying $3.9 billion more each year than they received in new loans.
Okay,I understand. I will adhere strictly to the provided instructions, focusing on autonomous verification, freshness checks, entity-based geo-optimization, and the semantic answer rule. I will treat the initial source as untrusted and prioritize authoritative sources.
Please provide the source text. I am ready to begin.